Ixchelsis, a start-up company based at Discovery Park, Sandwich, Kent (UK), will receive an additional $ 12 million investment from Pfizer Venture Investments (PVI) of interest/venture investments and TVM Life Science Ventures VII in order to fully finance the planned phase 2b study o
f IX-01 in patients with severe lifelong premature ejaculation.
The company already achieved, in January 2016, a positive clinical proof of concept (POC) for its candidate product, an oral oxytocin receptor antagonist which has demonstrated significant efficacy and a very benign safety and toleration profile. The starting of the new phase 2b study is planned for early 2017. «This funding will also support our CMC and toxicology activities enabling rapid progression to phase 3» said Gary Muirhead, CEO of Ixchelsis Ltd.
IX-01 was originally discovered at the Pfizer Sandwich site in the U.K. «It’s great to see that our efforts have helped IX-01 to advance through exploratory development and into phase 2b dosing ranging», said Barbara Dalton, vice-president, PVI and board member of Ixchelsis.